<DOC>
	<DOCNO>NCT00466466</DOCNO>
	<brief_summary>This study aim establish tolerable dose level regimen RAD001 combination cisplatin etoposide ( standard-of-care chemotherapy ) patient extensive stage small-cell lung cancer ( SCLC ) previously treat systemic chemotherapy .</brief_summary>
	<brief_title>Safety RAD001 Combination With Cisplatin Etoposide Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Patients histologically cytologically confirm diagnosis extensive disease smallcell lung cancer ( ED SCLC ) Age ≥ 18 year WHO Performance Status Grade ≤ 1 ( ie . ability perform normal daily function ) Adequate bone marrow , liver renal function Exclusion criterion : Chronic steroid treatment Prior treatment chemotherapy advance lung cancer Prior treatment mTOR inhibitor Active bleed condition , skin condition , gastrointestinal disorder , mouth ulcer , eye condition , chronic liver kidney disorder , uncontrolled diabetes , infection severe medical condition Symptomatic uncontrolled brain metastasis Other cancer within past 5 year Pregnant breastfeeding woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Small-Cell Lung Cancer</keyword>
	<keyword>SCLC</keyword>
	<keyword>Advanced Lung Cancer</keyword>
	<keyword>RAD</keyword>
	<keyword>RAD001</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Etoposide</keyword>
</DOC>